🚀 VC round data is live in beta, check it out!
InventisBio Valuation Multiples
Discover revenue and EBITDA valuation multiples for InventisBio and similar public comparables like ANI Pharmaceuticals, Taysha GTx, Lotus Pharmaceutical, Palvella Therapeutics and more.
InventisBio Overview
About InventisBio
InventisBio Co Ltd is an innovative drug research and development enterprise based in China with a global perspective, focusing on major diseases such as tumors and metabolic diseases. It has independently developed a series of innovative targeted drugs with patent protection, covering non-small cell lung cancer, breast cancer, colorectal cancer and other solid tumors, as well as hyperuricemia and metabolic diseases such as gout.
Founded
2013
HQ
Employees
N/A
Website
Financials (LTM)
EV
$2B
InventisBio Financials
InventisBio reported last 12-month revenue of $10M and negative EBITDA of ($46M).
In the same LTM period, InventisBio generated ($46M) in EBITDA losses and had net loss of ($45M).
Revenue (LTM)
InventisBio P&L
In the most recent fiscal year, InventisBio reported revenue of $5M and EBITDA of ($44M).
InventisBio expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $10M | XXX | $5M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $5M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 87% | XXX | XXX | XXX |
| EBITDA | ($46M) | XXX | ($44M) | XXX | XXX | XXX |
| EBITDA Margin | (439%) | XXX | (808%) | XXX | XXX | XXX |
| EBIT Margin | (435%) | XXX | (838%) | XXX | XXX | XXX |
| Net Profit | ($45M) | XXX | ($46M) | XXX | XXX | XXX |
| Net Margin | (435%) | XXX | (838%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
InventisBio Stock Performance
InventisBio has current market cap of $2B, and enterprise value of $2B.
Market Cap Evolution
InventisBio's stock price is $3.23.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $2B | -0.1% | XXX | XXX | XXX | $-0.08 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialInventisBio Valuation Multiples
InventisBio trades at 158.3x EV/Revenue multiple, and (36.1x) EV/EBITDA.
EV / Revenue (LTM)
InventisBio Financial Valuation Multiples
As of April 21, 2026, InventisBio has market cap of $2B and EV of $2B.
Equity research analysts estimate InventisBio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
InventisBio has a P/E ratio of (41.3x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/Revenue | 158.3x | XXX | 301.3x | XXX | XXX | XXX |
| EV/EBITDA | (36.1x) | XXX | (37.3x) | XXX | XXX | XXX |
| EV/EBIT | (36.4x) | XXX | (35.9x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 348.1x | XXX | XXX | XXX |
| P/E | (41.3x) | XXX | (40.8x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (69.2x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified InventisBio Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
InventisBio Margins & Growth Rates
InventisBio's revenue in the last 12 month grew by 110%.
InventisBio's rule of 40 is 103% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
InventisBio's rule of X is 553% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
InventisBio Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 110% | XXX | 300% | XXX | XXX | XXX |
| EBITDA Margin | (439%) | XXX | (808%) | XXX | XXX | XXX |
| EBITDA Growth | (6%) | XXX | (3%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 103% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 553% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 78% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 874% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 972% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
InventisBio Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| InventisBio | XXX | XXX | XXX | XXX | XXX | XXX |
| ANI Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Taysha GTx | XXX | XXX | XXX | XXX | XXX | XXX |
| Lotus Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| Palvella Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharvaris | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
InventisBio M&A Activity
InventisBio acquired XXX companies to date.
Last acquisition by InventisBio was on XXXXXXXX, XXXXX. InventisBio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by InventisBio
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialInventisBio Investment Activity
InventisBio invested in XXX companies to date.
InventisBio made its latest investment on XXXXXXXX, XXXXX. InventisBio invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by InventisBio
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout InventisBio
| When was InventisBio founded? | InventisBio was founded in 2013. |
| Where is InventisBio headquartered? | InventisBio is headquartered in China. |
| Is InventisBio publicly listed? | Yes, InventisBio is a public company listed on Shanghai Stock Exchange. |
| What is the stock symbol of InventisBio? | InventisBio trades under 688382 ticker. |
| When did InventisBio go public? | InventisBio went public in 2022. |
| Who are competitors of InventisBio? | InventisBio main competitors are ANI Pharmaceuticals, Taysha GTx, Lotus Pharmaceutical, Palvella Therapeutics. |
| What is the current market cap of InventisBio? | InventisBio's current market cap is $2B. |
| What is the current revenue of InventisBio? | InventisBio's last 12 months revenue is $10M. |
| What is the current revenue growth of InventisBio? | InventisBio revenue growth (NTM/LTM) is 110%. |
| What is the current EV/Revenue multiple of InventisBio? | Current revenue multiple of InventisBio is 158.3x. |
| Is InventisBio profitable? | No, InventisBio is not profitable. |
| What is the current EBITDA of InventisBio? | InventisBio has negative EBITDA and is not profitable. |
| What is InventisBio's EBITDA margin? | InventisBio's last 12 months EBITDA margin is (439%). |
| What is the current EV/EBITDA multiple of InventisBio? | Current EBITDA multiple of InventisBio is (36.1x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.